Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis

Author： Martin Robert C. G.   Scoggins Charles R.   Schreeder Marshall   Rilling William S.   Laing Christopher J.   Tatum Clifton M.   Kelly Lawrence R.   Garcia-Monaco Ricardo D.   Sharma Vivek R.   Crocenzi Todd S.   Strasberg Steven M.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|20|3649-3658

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.20, 2015-10, pp. : 3649-3658

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

By Madajewicz Stefan  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 772-778

Springer Publishing Company

Access to resources Recommend Favorite

Flutamide in unresectable pancreatic adenocarcinoma: A randomized, double-blind, placebo-controlled trial

By Negi Sanjay   Agarwal Anil   Chaudhary Adarsh  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 189-194

Springer Publishing Company

Access to resources Recommend Favorite

Drug-eluting stents appear favourable for diabetic patients

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 587, 2009-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Differences between drug-eluting stents in patients with diabetes

By  

Reactions Weekly, Vol. 1, Iss. 1415, 2012-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Drug-eluting stents beneficial for high-risk patients

By  

Inpharma, Vol. 1, Iss. 1609, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite